Abstract
Background: We recently reported that self-evaluation of the incidence and severity of treatment-related side effects (TSEs) using a National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0-based questionnaire was feasible and more informative than doctor reports in patients undergoing standard adjuvant chemotherapy for operable breast cancer. Here, we compare self- and doctor-evaluated day of onset and duration of TSEs in the same population. Patients and methods: Six hundred and four patients were enrolled at 11 sites in Italy. CTCAE v4.0 definitions of grade of severity of nausea, vomiting, constipation, anorexia, dysgeusia, diarrhea, fatigue, pain, paresthesia, and dyspnea were translated into Italian and rephrased. Questionnaires were administered after the first and third chemotherapy cycles. At each time-point, information on TSEs was extracted from the medical charts and compared to patient questionnaires. Results: A total of 594 and 573 paired patient and doctor questionnaires were collected after cycles one and three, respectively. TSE duration was significantly longer when reported by patients compared to doctors for six and seven of ten items after cycles one and three, respectively. Due to the combined effect of doctor underreporting of TSE incidence and duration, the mean percentages of cycle days with TSEs were significantly higher for all ten items when based on patient reports. Day of onset could not be evaluated because of insufficient numbers of complete records. Conclusions: Self-reporting TSE duration is feasible using a CTCAE-derived questionnaire. As doctors tend to underestimate TSE incidence and duration, patient-reported outcomes should be incorporated into clinical practice, perhaps using eHealth technologies, to harness their potential to better estimate total TSE burden.
| Original language | English |
|---|---|
| Pages (from-to) | 4339-4344 |
| Number of pages | 6 |
| Journal | Cancer Medicine |
| Volume | 7 |
| Issue number | 9 |
| DOIs | |
| Publication status | Published - Sep 1 2018 |
Fingerprint
Keywords
- adjuvant chemotherapy
- breast cancer
- chemotherapy-related side effects
- common toxicity criteria for adverse events
- duration
- patient-reported outcomes
ASJC Scopus subject areas
- Oncology
- Radiology Nuclear Medicine and imaging
- Cancer Research
Cite this
Self-evaluation of duration of adjuvant chemotherapy side effects in breast cancer patients : A prospective study. / Galizia, Danilo; Milani, Andrea; Geuna, Elena; Martinello, Rossella; Cagnazzo, Celeste; Foresto, Manuela; Longo, Virginia; Berchialla, Paola; Solinas, Gianfranca; Calori, Adele; Grasso, Bruna; Volpone, Chiara; Bertola, Gisella; Parola, Gisella; Tealdi, Giancarla; Giuliano, Piero Luigi; Ballari, Anna Maria; Aglietta, Massimo; Montemurro, Filippo.
In: Cancer Medicine, Vol. 7, No. 9, 01.09.2018, p. 4339-4344.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Self-evaluation of duration of adjuvant chemotherapy side effects in breast cancer patients
T2 - A prospective study
AU - Galizia, Danilo
AU - Milani, Andrea
AU - Geuna, Elena
AU - Martinello, Rossella
AU - Cagnazzo, Celeste
AU - Foresto, Manuela
AU - Longo, Virginia
AU - Berchialla, Paola
AU - Solinas, Gianfranca
AU - Calori, Adele
AU - Grasso, Bruna
AU - Volpone, Chiara
AU - Bertola, Gisella
AU - Parola, Gisella
AU - Tealdi, Giancarla
AU - Giuliano, Piero Luigi
AU - Ballari, Anna Maria
AU - Aglietta, Massimo
AU - Montemurro, Filippo
PY - 2018/9/1
Y1 - 2018/9/1
N2 - Background: We recently reported that self-evaluation of the incidence and severity of treatment-related side effects (TSEs) using a National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0-based questionnaire was feasible and more informative than doctor reports in patients undergoing standard adjuvant chemotherapy for operable breast cancer. Here, we compare self- and doctor-evaluated day of onset and duration of TSEs in the same population. Patients and methods: Six hundred and four patients were enrolled at 11 sites in Italy. CTCAE v4.0 definitions of grade of severity of nausea, vomiting, constipation, anorexia, dysgeusia, diarrhea, fatigue, pain, paresthesia, and dyspnea were translated into Italian and rephrased. Questionnaires were administered after the first and third chemotherapy cycles. At each time-point, information on TSEs was extracted from the medical charts and compared to patient questionnaires. Results: A total of 594 and 573 paired patient and doctor questionnaires were collected after cycles one and three, respectively. TSE duration was significantly longer when reported by patients compared to doctors for six and seven of ten items after cycles one and three, respectively. Due to the combined effect of doctor underreporting of TSE incidence and duration, the mean percentages of cycle days with TSEs were significantly higher for all ten items when based on patient reports. Day of onset could not be evaluated because of insufficient numbers of complete records. Conclusions: Self-reporting TSE duration is feasible using a CTCAE-derived questionnaire. As doctors tend to underestimate TSE incidence and duration, patient-reported outcomes should be incorporated into clinical practice, perhaps using eHealth technologies, to harness their potential to better estimate total TSE burden.
AB - Background: We recently reported that self-evaluation of the incidence and severity of treatment-related side effects (TSEs) using a National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0-based questionnaire was feasible and more informative than doctor reports in patients undergoing standard adjuvant chemotherapy for operable breast cancer. Here, we compare self- and doctor-evaluated day of onset and duration of TSEs in the same population. Patients and methods: Six hundred and four patients were enrolled at 11 sites in Italy. CTCAE v4.0 definitions of grade of severity of nausea, vomiting, constipation, anorexia, dysgeusia, diarrhea, fatigue, pain, paresthesia, and dyspnea were translated into Italian and rephrased. Questionnaires were administered after the first and third chemotherapy cycles. At each time-point, information on TSEs was extracted from the medical charts and compared to patient questionnaires. Results: A total of 594 and 573 paired patient and doctor questionnaires were collected after cycles one and three, respectively. TSE duration was significantly longer when reported by patients compared to doctors for six and seven of ten items after cycles one and three, respectively. Due to the combined effect of doctor underreporting of TSE incidence and duration, the mean percentages of cycle days with TSEs were significantly higher for all ten items when based on patient reports. Day of onset could not be evaluated because of insufficient numbers of complete records. Conclusions: Self-reporting TSE duration is feasible using a CTCAE-derived questionnaire. As doctors tend to underestimate TSE incidence and duration, patient-reported outcomes should be incorporated into clinical practice, perhaps using eHealth technologies, to harness their potential to better estimate total TSE burden.
KW - adjuvant chemotherapy
KW - breast cancer
KW - chemotherapy-related side effects
KW - common toxicity criteria for adverse events
KW - duration
KW - patient-reported outcomes
UR - http://www.scopus.com/inward/record.url?scp=85050930703&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85050930703&partnerID=8YFLogxK
U2 - 10.1002/cam4.1687
DO - 10.1002/cam4.1687
M3 - Article
AN - SCOPUS:85050930703
VL - 7
SP - 4339
EP - 4344
JO - Cancer Medicine
JF - Cancer Medicine
SN - 2045-7634
IS - 9
ER -